INTRODUCTION
Advanced Enzyme Technologies Ltd. (NSE: ADVENZYMES | BSE: 540025) released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27) following a Board of Directors meeting on August 08, 2026. The Indian specialty enzyme and bioprocessing manufacturer reported a modest year-on-year expansion in its core top-line revenue, alongside a contraction in net profitability driven by elevated input material consumption costs and rising employee expenses.
Alongside the quarterly earnings report, the Board approved a share buyback program via the open market stock exchange route worth up to ₹69.70 crore at a ceiling price of ₹500 per share. Furthermore, the company announced strategic capital allocation moves, including acquiring the remaining 4.28% equity stake in its subsidiary JC Biotech Private Limited to make it a wholly owned subsidiary, and infusing additional growth capital into Advanced Nutrazyme Private Limited.
For global and domestic investors, Q1 FY27 highlights steady operational revenue, shifting cost dynamics, and corporate restructuring designed to simplify group operations and optimize balance sheet cash.
┌─────────────────────────────────────────────────────────────────────────┐
│ ADVANCED ENZYME TECHNOLOGIES Q1 FY27 AT A GLANCE │
├──────────────────────────────┬──────────────┬──────────────┬────────────┤
│ Consolidated Metric │ Q1 FY27 │ Q1 FY26 │ YoY Change │
├──────────────────────────────┼──────────────┼──────────────┼────────────┤
│ Revenue from Operations │ ₹189.79 Cr │ ₹185.91 Cr │ +2.08% │
│ EBITDA │ ₹63.99 Cr │ ₹65.28 Cr │ -1.98% │
│ EBITDA Margin (%) │ 33.72% │ 35.12% │ -140 bps │
│ Profit Before Tax (PBT) │ ₹53.53 Cr │ ₹54.90 Cr │ -2.50% │
│ Net Profit (PAT) │ ₹38.59 Cr │ ₹40.44 Cr │ -4.58% │
│ Diluted EPS (₹) │ ₹3.31 │ ₹3.57 │ -7.28% │
└──────────────────────────────┴──────────────┴──────────────┴────────────┘
KEY HIGHLIGHTS
Revenue Growth: Consolidated revenue from operations reached ₹189.79 crore in Q1 FY27, representing a 2.08% increase compared to ₹185.91 crore in Q1 FY26.
Profitability Pressure: Consolidated net profit after tax (PAT) stood at ₹38.59 crore, declining 4.58% year-on-year from ₹40.44 crore in the corresponding prior-year period.
Sequential Contraction: Revenue fell 6.68% quarter-on-quarter against ₹203.37 crore in Q4 FY26, while PAT dropped 14.72% sequentially from ₹45.25 crore.
Share Buyback Approval: The Board authorized the buyback of up to 13.94 lakh equity shares at a price not exceeding ₹500 per share, utilizing up to ₹69.70 crore of cash reserves.
Strategic Subsidiary Buyout: Approved the acquisition of the remaining 4.28% equity stake in JC Biotech Private Limited for ₹7.98 crore, turning it into a 100% wholly owned subsidiary.
Subsidiary Capital Infusion: Approved an additional fund infusion of up to ₹2.00 crore in Advanced Nutrazyme Private Limited to expand distribution for nutrition and wellness products.
Q1 FY27 FINANCIAL RESULTS
Advanced Enzyme Technologies reported consolidated revenue from operations of ₹189.79 crore during the quarter ended June 30, 2026, compared to ₹185.91 crore in Q1 FY26. Other income contributed ₹13.02 crore, lifting total consolidated income to ₹202.81 crore, up 4.13% YoY from ₹194.76 crore.
Total expenses for the quarter rose to ₹149.28 crore from ₹139.86 crore in Q1 FY26. Cost of materials consumed surged 23.95% YoY to ₹54.50 crore, up from ₹43.97 crore. Employee benefit expenses increased 12.18% YoY to ₹44.55 crore from ₹39.71 crore. Finance costs were maintained at ₹0.58 crore, while depreciation and amortization expenses stood at ₹9.88 crore.
CONSOLIDATED EXPENSE COMPOSITION (Q1 FY27)
┌────────────────────────────────────────────────┬──────────────┐
│ Expense Head │ Amount (₹Cr) │
├────────────────────────────────────────────────┼──────────────┤
│ Cost of Materials Consumed │ ₹54.50 Cr │
│ Employee Benefits Expense │ ₹44.55 Cr │
│ Other Expenses │ ₹44.58 Cr │
│ Depreciation & Amortization │ ₹9.88 Cr │
│ Changes in Inventories (Finished/WIP) │ -₹4.81 Cr │
│ Finance Costs │ ₹0.58 Cr │
├────────────────────────────────────────────────┼──────────────┤
│ Total Expenses │ ₹149.28 Cr │
└────────────────────────────────────────────────┴──────────────┘
Standalone revenue from operations for Q1 FY27 was recorded at ₹115.86 crore, down 7.33% YoY from ₹125.02 crore in Q1 FY26. Standalone net profit stood at ₹22.35 crore compared to ₹73.98 crore in Q1 FY26 (Note: Q1 FY26 standalone profit included non-recurring dividend/other income streams).
Q1 FY27 VS Q1 FY26 VS Q4 FY26 COMPARISON
The following table provides a comparison of Advanced Enzyme Technologies’ consolidated financial results across Q1 FY27, Q1 FY26, and Q4 FY26.
Consolidated Financial Performance Comparison
(All financial figures in ₹ Crore, except EPS and Margins)
| Metric | Q1 FY27 | Q1 FY26 | YoY Change (%) | Q4 FY26 | QoQ Change (%) |
Revenue from Operations | 189.79 | 185.91 | +2.08% | 203.37 | -6.68% |
Other Income | 13.02 | 8.85 | +47.12% | 7.23 | +80.08% |
Total Income | 202.81 | 194.76 | +4.13% | 210.60 | -3.70% |
Cost of Raw Materials | 54.50 | 43.97 | +23.95% | 55.96 | -2.61% |
Employee Expenses | 44.55 | 39.71 | +12.18% | 41.94 | +6.22% |
Total Expenses | 149.28 | 139.86 | +6.73% | 150.90 | -1.07% |
| EBITDA | 63.99 | 65.28 | -1.98% | 70.46 | -9.18% |
| EBITDA Margin (%) | 33.72% | 35.12% | -140 bps | 34.65% | -93 bps |
Profit Before Tax (PBT) | 53.53 | 54.90 | -2.50% | 59.80 | -10.48% |
Tax Expense | 14.94 | 14.46 | +3.32% | 14.55 | +2.68% |
Net Profit (PAT) | 38.59 | 40.44 | -4.58% | 45.25 | -14.72% |
| PAT Margin (%) | 20.33% | 21.75% | -142 bps | 22.25% | -192 bps |
Diluted EPS (₹) | 3.31 | 3.57 | -7.28% | 3.84 | -13.80% |
REVENUE AND PROFIT ANALYSIS
Revenue from operations delivered a moderate YoY expansion of 2.08% to ₹189.79 crore. Top-line trajectory continues to reflect steady baseline demand for enzyme formulations across key end-user segments. However, revenue growth fell short of offsetting operational cost inflation.
Cost of materials consumed rose to ₹54.50 crore from ₹43.97 crore in Q1 FY26, representing a raw-material-to-revenue ratio of 28.72% compared to 23.65% in the prior-year period. This cost expansion reflects higher substrate input prices, shifts in product mix toward lower-margin enzyme blends, and input cost dynamics in specialty fermentation raw materials.
CONSOLIDATED REVENUE & PAT TREND (₹ CRORE)
250 ┬───────────────────────────────────────────────────────────
│
200 ┼─────────────────185.91──────────203.37──────────189.79──── Operational Revenue
│
150 ┼───────────────────────────────────────────────────────────
│
100 ┼───────────────────────────────────────────────────────────
│
50 ┼──────────────────40.44───────────45.25───────────38.59──── Net Profit (PAT)
│
0 ┴────────────────Q1 FY26─────────Q4 FY26─────────Q1 FY27───
On a sequential basis, revenue contracted by 6.68% from Q4 FY26 levels. This sequential drop aligns with historical seasonal demand cycles in human and animal nutrition segments, where fourth-quarter inventory building by international distributors typically leads to a quieter first quarter. Net profit dropped 14.72% QoQ to ₹38.59 crore due to higher employee benefit charges and operating leverage contraction on lower top-line volume.
EBITDA AND MARGIN ANALYSIS
Operating EBITDA for Q1 FY27 came in at ₹63.99 crore, down 1.98% from ₹65.28 crore in Q1 FY26. Consolidated EBITDA margin contracted by 140 basis points YoY to 33.72% from 35.12%.
CONSOLIDATED EBITDA MARGIN TRAJECTORY (%)
40% ┬───────────────────────────────────────────────────────────
│ 35.12% 34.65% 33.72%
30% ┼───────────────────────────────────────────────────────────
│
20% ┼───────────────────────────────────────────────────────────
│
10% ┼───────────────────────────────────────────────────────────
│
0% ┴────────────────Q1 FY26─────────Q4 FY26─────────Q1 FY27───
The margin compression stemmed primarily from raw material cost expansion and employee compensation increments. Employee benefit costs increased to ₹44.55 crore, representing 23.47% of revenue from operations compared to 21.36% in Q1 FY26.
Other expenses remained well controlled at ₹44.58 crore compared to ₹39.72 crore in Q1 FY26, expanding at a pace consistent with general administrative cost inflation. Higher other income of ₹13.02 crore provided cushion at the PBT level, restricting the YoY decline in PBT to 2.50%.
SEGMENT-WISE PERFORMANCE
Under Indian Accounting Standard (Ind AS) 108, Advanced Enzyme Technologies operates under a single primary reporting business segment: “Manufacturing and sales of enzymes”. However, management monitors performance across key end-user market verticals:
PRIMARY END-USER APPLICATION VERTICALS
┌──────────────────────────────┬──────────────────────────────┬──────────────────────────────┐
│ Human Nutrition │ Animal Nutrition │ Bio-Processing │
├──────────────────────────────┼──────────────────────────────┼──────────────────────────────┤
│ • Dietary Supplements │ • Feed Enzymes for Poultry │ • Food Processing │
│ • Digestive Health Enzymes │ • Swine & Ruminant Nutrition │ • Textile Processing │
│ • Systemic Enzyme Formulations│ • Gut Health Solutions │ • Bio-catalysts for Pharma │
└──────────────────────────────┴──────────────────────────────┴──────────────────────────────┘
Segment Revenue Breakdown
(Figures in ₹ Crore based on company end-application reporting)
| Application Segment | Q1 FY27 Revenue | Q1 FY26 Revenue | YoY Growth (%) | Primary Revenue Driver |
| Human Nutrition | ~128.50 | ~126.80 | +1.34% | Probiotics, digestive enzymes, nutra blends |
| Animal Nutrition | ~21.20 | ~19.50 | +8.72% | Poultry feed enzyme adoption in India/Asia |
| Bio-Processing | ~24.80 | ~24.20 | +2.48% | Specialized food processing and textile enzymes |
| Specialty Non-Enzyme / Other | ~15.29 | ~15.41 | -0.78% | Specialized active ingredients and biotics |
Total Revenue | 189.79 | 185.91 | +2.08% | Consolidated top-line execution |
Human Nutrition: Remains the largest revenue generator, contributing over 67% of consolidated operational revenue. Steady sales of digestive enzymes and proprietary probiotic blends provided baseline volume.
Animal Nutrition: Experienced the strongest growth percentage among major verticals (+8.72% YoY), supported by increasing feed enzyme adoption across Indian and South Asian poultry markets.
Bio-Processing: Delivered modest growth, led by food processing enzyme demand (baking, fruit juice processing, starch processing), while industrial textile enzyme demand remained range-bound.
GEOGRAPHIC PERFORMANCE
Advanced Enzyme Technologies generates a significant portion of its sales from international markets, particularly North America and Europe.
GEOGRAPHIC REVENUE DISTRIBUTION
┌───────────────────────────────────────────────────────────┐
│ International Markets (Exports / US / Europe): ~55% │
├───────────────────────────────────────────────────────────┤
│ Domestic Market (India): ~45% │
└───────────────────────────────────────────────────────────┘
Domestic Market (India): Revenue performance in India was supported by stable human nutrition sales and expanding feed enzyme distribution.
North America: Generated through US subsidiaries (Advanced Enzymes USA, Cal India Foods, Enzyme Innovation), North America remains a core profit contributor. Demand for specialty digestive health and nutraceutical enzyme formulations stabilized following inventory rebalancing by US dietary supplement brand owners.
Europe & Rest of World: Operations handled via Advanced Enzymes Europe B.V. and Evoxx Technologies GmbH saw steady demand in specialized biocatalysis and industrial enzyme applications.
BUYBACK AND CAPITAL ALLOCATION
On August 08, 2026, the Board of Directors approved a share buyback program.
SHARE BUYBACK PROGRAM AT A GLANCE
┌──────────────────────────────────────┬──────────────────────────────────────┐
│ Maximum Buyback Size │ Up to ₹69.70 Crore (₹697 Million) │
│ Maximum Buyback Price │ ₹500 per Equity Share │
│ Indicative Max Shares to Buy Back │ 13,94,000 Equity Shares │
│ Percentage of Existing Equity Capital│ 1.24% of paid-up share capital │
│ Route / Mechanism │ Open Market via Stock Exchanges │
│ Promoters Participation │ Excluded (Public Shareholders Only) │
└──────────────────────────────────────┴──────────────────────────────────────┘
Key Buyback Details:
Size and Capital Limits: The Maximum Buyback Size of ₹69.70 crore represents 9.99% of standalone aggregate paid-up equity capital and free reserves, and 5.09% of consolidated paid-up capital and free reserves as of March 31, 2026. This falls within the 10% Board approval limit under the Companies Act, 2013.
Buyback Route: Conducted through the “Open Market” route via stock exchange trading mechanisms.
Price & Premium: The ceiling price of ₹500 per share represents a substantial premium over the prevailing market price of ~₹300–₹320, offering flexibility to execute purchases across prevailing market conditions.
Impact on Shareholding: Promoters and promoter group entities are excluded from participating in this buyback. Consequently, post-buyback promoter shareholding will increase from 43.24% to approximately 43.79% (assuming full deployment at the maximum buyback price and maximum shares).
PRE vs POST BUYBACK SHAREHOLDING STRUCTURE
┌────────────────────────────┬───────────────────┬───────────────────┐
│ Shareholder Category │ Pre-Buyback (%) │ Post-Buyback (%)* │
├────────────────────────────┼───────────────────┼───────────────────┤
│ Promoter & Promoter Group │ 43.24% │ 43.79% │
│ Public Shareholders │ 56.76% │ 56.21% │
├────────────────────────────┼───────────────────┼───────────────────┤
│ Total │ 100.00% │ 100.00% │
└────────────────────────────┴───────────────────┴───────────────────┘
*Note: Assumes full deployment of Maximum Buyback Size at Maximum Buyback Price.
Additional Capital Allocation & Corporate Restructuring Actions:
100% Ownership in JC Biotech: Approved the acquisition of the remaining 4.28% equity stake (8,86,544 equity shares) in JC Biotech Private Limited for ₹90 per share, totaling ₹7.98 crore. Upon completion by September 30, 2026, JC Biotech will become a 100% wholly owned subsidiary, simplifying corporate structure and operational synergies.
Capital Infusion in Advanced Nutrazyme: Approved infusing up to ₹2.00 crore into wholly owned subsidiary Advanced Nutrazyme Private Limited (ANPL) via equity or inter-corporate deposits to scale up marketing and distribution of the company’s nutrition and wellness portfolio.
WHAT MANAGEMENT IS SAYING
In disclosures and notes accompanying the quarterly statement, management highlighted key operational context:
Subsidiary Synergies: The acquisition of the remaining minority stake in JC Biotech is aimed at optimizing business synergies across research, fermentation infrastructure, and production scheduling.
B2C and Wellness Push: The capitalization of Advanced Nutrazyme Private Limited reflects management’s commitment to building out direct commercialization channels for finished human nutrition and wellness products.
Litigation Resolution in US Subsidiary: Notes to consolidated accounts confirmed that court proceedings involving US subsidiary Advanced Supplementary Technologies Corporation (AST) resulted in favorable orders from the US Court of Appeals, leading to the previous reversal of legal provisions totaling ₹16.14 crore during FY26.
ESOP Allotments: The company allotted 49,350 equity shares during the quarter under its Employee Stock Option Scheme 2022 (ESOP Scheme 2022).
WHAT DRIVES ADVANCED ENZYME TECHNOLOGIES’ BUSINESS
To evaluate Advanced Enzyme Technologies, investors must understand its position within the global biotechnology value chain.
BIOTECHNOLOGY VALUE CHAIN
┌───────────────────────┐ ┌───────────────────────┐ ┌───────────────────────┐
│ Primary Research & │───>│ Substrate & Aerobic │───>│ Custom Formulation, │
│ Strain Isolation │ │ Fermentation │ │ Blending & Packaging │
└───────────────────────┘ └───────────────────────┘ └───────────────────────┘
Enzymes are biological catalysts—specialized proteins produced by living organisms—that accelerate chemical reactions without being consumed in the process. Advanced Enzyme Technologies specializes in research, development, manufacturing, and application of proprietary enzymes and probiotics.
Core Business Strengths:
Vertical Integration: The company operates across the entire enzyme value chain, from strain isolation and genetic engineering to large-scale submerged/solid-state fermentation, extraction, and customized formulation blending.
High Barriers to Entry: Enzyme manufacturing requires deep proprietary microorganism libraries, fermentation expertise, regulatory clearances (US FDA, EFSA, FSSAI), and extensive clinical validation.
Diverse End-User Applications: Products serve dietary supplement brands, animal feed producers, pharmaceutical active ingredient manufacturers, food processing units (baking, dairy, brewing), and eco-friendly textile processing units.
WHY THE Q1 FY27 RESULTS MATTER
Advanced Enzyme Technologies’ Q1 FY27 performance presents a mixed operational outcome.
┌──────────────────────────────────────────────────┬──────────────────────────────────────────────────┐
│ Positives │ Areas to Monitor │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┤
│ • Top-line resilience with 2.08% YoY growth │ • YoY net profit decline of 4.58% │
│ • Strong EBITDA margins maintained at 33.72% │ • Raw material cost expansion (+23.95% YoY) │
│ • Buyback provides downside price support │ • Sequential contraction in volume and revenue │
│ • Full acquisition of JC Biotech simplifies group│ • Rising employee cost structure │
└──────────────────────────────────────────────────┴──────────────────────────────────────────────────┘
The quarter highlights top-line resilience alongside input cost inflation. Despite raw material price increases, the company maintained an operating EBITDA margin above 33%, demonstrating the pricing power inherent in specialized enzyme formulations.
The capital allocation strategy—combining a ₹69.70 crore open-market buyback with minority buyout in JC Biotech—demonstrates management’s willingness to deploy excess cash reserves to enhance shareholder value and streamline corporate governance.
BALANCE SHEET AND CASH FLOW
Advanced Enzyme Technologies maintains a cash-rich, low-debt balance sheet structure.
Debt Profile: Consolidated finance costs for Q1 FY27 stood at ₹0.58 crore, reflecting negligible long-term bank borrowings.
Liquidity & Working Capital: Total consolidated reserves and surplus stood at ₹1,609.57 crore as of March 31, 2026. Cash reserves are sufficient to fund the ₹69.70 crore buyback, the ₹7.98 crore JC Biotech minority buyout, and the ₹2.00 crore ANPL investment entirely through internal accruals without taking on debt.
Working Capital Efficiency: Operating cash flow generation remains healthy, though raw material inventory building slightly expanded working capital requirements during the quarter.
STOCK MARKET REACTION
Ahead of the earnings disclosure on Saturday, August 08, 2026, Advanced Enzyme Technologies Ltd stock closed on Friday, August 07, 2026, at ₹312.45 on the National Stock Exchange (NSE), up 1.15% for the session.
STOCK TRADING SNAPSHOT (AUGUST 07, 2026)
┌───────────────────────────────────────┬───────────────────────────────────────┐
│ NSE Symbol: ADVENZYMES │ BSE Code: 540025 │
├───────────────────────────────────────┼───────────────────────────────────────┤
│ Closing Market Price: ₹312.45 │ Market Capitalization: ~₹3,498 Crore │
│ 52-Week High / Low: ₹428.00 / ₹272.10 │ Trailing P/E Ratio: ~20.2x │
└───────────────────────────────────────┴───────────────────────────────────────┘
The stock traded in a 52-week range of ₹272.10 to ₹428.00. Market reaction during the subsequent trading session is expected to reflect a balance between the modest contraction in quarterly net profit and the positive capital allocation impact of the share buyback at a maximum price of ₹500.
GROWTH OPPORTUNITIES
Expanding Probiotic & Gut Health Solutions: Combining enzyme formulations with proprietary probiotic strains offers growth potential in human dietary supplements across North America and Europe.
Biocatalysis in Pharmaceutical API Manufacturing: Replacing traditional chemical catalysts with enzymatic biocatalysts in active pharmaceutical ingredient (API) synthesis offers green chemistry advantages and cost efficiencies for global pharma clients.
Animal Feed Enzyme Adoption: Penetration of phytase, protease, and carbohydrate-degrading enzymes in poultry and swine feed markets across India and Southeast Asia presents volume expansion opportunities.
Direct Consumer Wellness Channel: Capitalizing Advanced Nutrazyme Private Limited enables direct marketing of finished nutraceutical brands.
KEY RISKS
Raw Material Price Volatility: Fluctuations in agricultural substrates, specialized growth media, and fermentation inputs directly impact gross margins.
Foreign Exchange Fluctuations: With over 50% of revenue coming from international sales, sharp movements in USD/INR and EUR/INR rates create translation and transaction exposure.
Regulatory Approvals: Delays in securing novel food certifications, EFSA clearances, or US FDA regulatory approvals for new enzyme strains can postpone product launches.
Client Inventory Rebalancing: Concentrated inventory cutbacks by large US nutraceutical brand owners can disrupt quarterly export billing schedules.
INVESTOR OUTLOOK
INVESTOR SCENARIO ANALYSIS
┌──────────────────────────┬──────────────────────────┬──────────────────────────┐
│ Bull Case │ Base Case │ Bear Case │
├──────────────────────────┼──────────────────────────┼──────────────────────────┤
│ • Export growth >12% │ • Top-line growth 6-8% │ • Raw material inflation │
│ • EBITDA margins >36% │ • EBITDA margins 33-35% │ erodes margins <30% │
│ • Swift US market rebound│ • Modest growth in India │ • Regulatory delays for │
│ • EPS expansion post- │ • Neutral impact post- │ new enzyme strains │
│ buyback execution │ buyback completion │ • Export volume slowdown │
└──────────────────────────┴──────────────────────────┴──────────────────────────┘
Bull Case
Accelerated order inflows from US and European human nutrition customers post-inventory rebalancing.
Gross margin recovery as raw material input prices normalize, lifting EBITDA margins toward 36%.
EPS enhancement resulting from share count reduction following the buyback execution.
Base Case
Single-digit revenue growth (6–8% YoY) backed by stable domestic feed and human nutrition demand.
EBITDA margins remaining in the 33–35% corridor amid stable overhead control.
Steady cash generation funding organic capex and small bolt-on subsidiary acquisitions.
Bear Case
Continued raw material price inflation squeezing gross margins below 30%.
Protracted weakness in international export demand for dietary supplement enzymes.
Adverse foreign exchange movements impacting overseas earnings realization.
WHAT INVESTORS SHOULD WATCH IN Q2 FY27
Buyback Execution: Progress, average purchase price, and total deployment under the open-market buyback program.
Gross Margin Trajectory: Whether material cost as a percentage of revenue moderates from Q1 FY27’s 28.72% level.
Export Recovery Signals: Revenue commentary from US subsidiaries regarding dietary supplement order intake.
Integration Progress: Completion of the JC Biotech 100% equity stake acquisition by September 30, 2026.
FINAL TAKE: WHAT Q1 FY27 TELLS INVESTORS
Advanced Enzyme Technologies’ Q1 FY27 earnings report highlights top-line stability, solid operating margin retention above 33%, and disciplined balance sheet management. While cost inflation trimmed net profit by 4.58% YoY, the company’s operating fundamentals remain sound.
The Board’s approval of a ₹69.70 crore buyback at a maximum price of ₹500 per share, combined with corporate restructuring to achieve 100% ownership in JC Biotech, signals confidence in long-term earnings capability and a commitment to efficient capital deployment. Investors should monitor gross margin developments and export volume recovery in upcoming q
